Inhaled Prostacyclin, Iloprost, Ventavist, for Pulmonary Hypertension

LUNG (PULMONARY): MAIN MENU

Pulmonary Hypertension

What is PH?
Primary PH
Isolated PH
Secondary PH

Exercised Induced PH
PH Disease Correlations
Symptoms
Diagnosis

Prognosis
Treatments
Research Registries

Research
Patient Support Organizations
Personal Stories

Treatments for Pulmonary Hypertension

Bosentan/Tracleer
Endothelin Receptors (Sitaxsentan/Ambrisentan)
Inhaled Prostacyclin (Ventavis, Iloprost)
Heart/Lung Transplants

Prostacyclin (Flolan, Epoprostenol) Warning
Sildenafil Citrate (Revatio, Viagra)
Stem Cell Transplant
Warfarin (Coumadin)

Inhaled Prostacyclin (Iloprost, Ventavist)

Use Of Bosentan And Continuous Iloprost Infusion In Scleroderma Patient With Pulmunary Hypertension. Continuous IV infusion of iloprost associated with bosentan in SSc patients with PAPs improved symptoms of PAPs, hemodynamics and physical aspects of quality of life. M. M. S. SESSAREGO AB0529 EULAR 2007. (Also see: Bosentan )

Randomized Study of Adding Inhaled Iloprost to Existing Bosentan in Pulmonary Arterial Hypertension. Results of this limited study demonstrate that the addition of inhaled iloprost in patients with PAH with reduced exercise capacity on bosentan monotherapy is safe and effective. American Journal of Respiratory and Critical Care Medicine Vol 174. pp. 1257-1263, (2006).

Combo Therapy Superior for Pulmonary Arterial Hypertension. Combining Ventavis (iloprost) with Tracleer (bosentan) increased exercise capability, reduced clinical deterioration and, for some patients, improved diagnostic functional class by one stage compared with Tracleer alone. MedPage Today. 12/01/06.

Does cyclical iloprost infusion prevent severe isolated pulmonary hypertension (PAH) in systemic sclerosis? Preliminary results. In systemic sclerosis the multiple effects of iloprost on endothelium, platelets and cytokine network may counteract the vasospastic profile of lung microvasculature in PAH and the consequent vascular wall remodelling, thus preventing the development of severe illness. PubMed. Rheumatol Int. 2006 Sep 28.

New Ventavis Data Presented at CHEST Meeting. Phase II randomized clinical study for adding Ventavis® (iloprost) Inhalation Solution to stable doses of Tracleer® (bosentan) in patients with pulmonary arterial hypertension (PAH). Patients who received inhaled iloprost on top of oral bosentan not only tolerated the combination, but experienced enhanced treatment efficacy. PR Newswire. 10/31/05. (Also see: Bosentan)